KVUE
NYSEKenvue Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 12 recent filings. 11 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Smith Jeffrey C Director | Grant / award | 1.41K | — | — | 2026-06-29 |
ALLISON RICHARD E JR Director | Grant / award | 1.41K | — | — | 2026-06-29 |
Howlett Heather CFO & CAO | Sell (open market) | 3.7K | $18.11 | $66,988.50 | 2026-06-10 |
Smith Jeffrey C Director | Grant / award | 10.31K | $17.46 | $179,995.14 | 2026-05-21 |
Hofstetter Sarah Director | Grant / award | 10.31K | $17.46 | $179,995.14 | 2026-05-21 |
HOLDEN BETSY D Director | Grant / award | 10.31K | $17.46 | $179,995.14 | 2026-05-21 |
MERLO LARRY J Director | Grant / award | 16.04K | $17.46 | $279,988.56 | 2026-05-21 |
PRABHU VASANT M Director | Grant / award | 10.31K | $17.46 | $179,995.14 | 2026-05-21 |
Sneed Michael E Director | Grant / award | 10.31K | $17.46 | $179,995.14 | 2026-05-21 |
Curado Gomes de Lemos Leonardo Group President LATAM | Option exercise | 24.25K | $0.00 | — | 2026-05-01 |
Curado Gomes de Lemos Leonardo Group President LATAM | Tax withholding | 7.14K | $17.43 | $124,467.63 | 2026-05-01 |
Curado Gomes de Lemos Leonardo Group President LATAM | Option exercise | 24.25K | $0.00 | — | 2026-05-01 |
Source: SEC EDGAR Forms 4/4A (CIK 1944048). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$KVUE 19.5C 7/31 — 0.22 → 0.58 (+163%)
$KVUE $19.5 31 JUL 26 (W) CALL 100 $0.22 ➡️ $0.58 163% GAINER!
$KVUE 19.5C 7/31 — 0.22 → 0.58 (+163%)
$JNJ $KVUE $SPX Reality sinks in lol 😝 Requires 95% of plaintiffs approve 99% of the lawyers approved because they are getting 40-50% of the 5.5 Billion lol 😂 plus the PSC lawyers are getting 5-8% means plaintiffs getting 50% 🤣🙈🤔 good luck Junk n Junk 🤣💰👋
$KVUE 🧴 $19.5 31 JUL 26 (W) CALL 100 $0.22 ➡️ $0.44 🤑 100% GAINER! ☢️ HIT THE FOLLOW AND TURN MY POST NOTIFICATIONS ON! 🔔
$KVUE $19.5 31 JUL 26 (W) CALL 100 $0.22 ➡️ $0.44 100% GAINER!
$JNJ $KVUE $SPX Settlement requires 95% approval rate, deal was pushed by the court magistrate and PSC lawyers 😆💰 Never going to be approved by plaintiffs lol 😂 lowball offer
Johnson & Johnson reached a proposed settlement to resolve most U.S. ovarian cancer lawsuits linked to its talc products, agreeing to pay $5.5 billion if at least 95% of claimants accept. The deal would cover about 76,000 pending claims and end more than 15 years of litigation. The agreement follows a federal court ruling that raised doubts about whether plaintiffs could prove J&J’s talc caused ovarian cancer in specific cases. J&J said it remains confident it would have prevailed at trial but chose to settle to avoid the costs and uncertainty of prolonged litigation. The first payment, capped at $3 billion, would be made in 2027, with no further payments before 2028. The company continues to maintain that scientific evidence supports the safety of its talc products, which it says were asbestos-free and did not cause cancer. J&J discontinued Johnson’s Baby Powder globally in 2023 and assumed all talc-related liabilities after spinning off its consumer health business, Kenvue. $JNJ $KVUE
Stopped $KVUE At Breakeven Price. Sold At $0.23.
Stopped $KVUE At Breakeven Price. Sold At $0.23.
Stopped $KVUE At Breakeven Price. Sold At $0.23
$KVUE 31 JUL 26 $19.5 CALL $0.22
Latest news
Kenvue's Q2 Earnings Coming Up: Here's What Lies Ahead of the Stock
Church & Dwight (CHD) Meets Q2 Earnings Estimates
Kenvue's Brand Strength and Growth Drivers Shape Its Future Outlook
Is Kenvue Stock Attractive After Margin Gains and Deal Uncertainty
Kenvue Benefits From Consumer Health Trends and Margin Expansion
Kenvue Increases Quarterly Cash Dividend
What Are Wall Street Analysts' Target Price for Kenvue Stock?
5 Dividend Kings Continued to Pay and Raise Dividends Through Every Market Crash Since Black Monday
Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)
Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.